Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Pozycja w akcjach #2306
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cena akcji
$64.24
Kapitalizacja rynkowa
$8.93B
Zmiana (1 dzień)
2.54%
Zmiana (1 rok)
8.24%
Kraj
US
Handel Cytokinetics, Incorporated (CYTK)

Kategoria

Healthcare
Historia podziałów akcji dla Cytokinetics, Incorporated (CYTK)
Akcje Cytokinetics, Incorporated (symbol: CYTK) przeszły łącznie 1 podziałów.
Najnowszy podział miał miejsce Jun 25, 2013.
Jedna akcja CYTK kupiona przed Jun 25, 2013 odpowiada dziś 0.16666666666667 akcjom CYTK.
Lista podziałów akcji
Rok Podział Mnożnik Skumulowany mnożnik
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
Podziały akcji dla podobnych firm lub konkurencji
Firma Liczba podziałów akcji Skumulowany mnożnik Kraj
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL